Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?Zacks Investment Research • 12/09/24
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?Zacks Investment Research • 11/29/24
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene TherapiesZacks Investment Research • 11/27/24
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a BetZacks Investment Research • 11/27/24
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA ProgramsBusiness Wire • 11/26/24
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD ProgramZacks Investment Research • 11/07/24
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/07/24
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 11/06/24
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga • 10/21/24
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society CongressBusiness Wire • 09/26/24
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?Zacks Investment Research • 09/06/24
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic YearBusiness Wire • 09/05/24
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • 08/30/24